Stage 4 Natural Killer Cells and Leukemia

Stage 4 Leukemia - A New Immunotherapy Brings Hope to Stage 4 Cancer Patients

Fight Against Stage 4 Cancer and Leukemia Strengthened by Immunotherapy

The field of cancer immunology has presently exceeded 30 years and has genuinely skyrocketed, particularly over the last decade. Immunotherapy, the use of the stimulated immune system to ward off disease, has morphed into different sub categories including immune system growth factors, monoclonal antibodies, cellular therapies, and even combinations of several of these strategies. Recent advances in adoptive immunotherapy (focused on the expansion of specific disease-fighting white blood cells and their infusion into patients) have led to colossal discoveries that will decidedly impact the treatment of Leukemia and other cancers over the span of the next ten years..

Making a Case for Immunotherapy as a Viable Treatment for Stage 4 Cancer and Advanced Stage Leukemia

Immunotherapy utilizes the immune system to disseminate chronic diseases, such as cancer. Various immunotherapy strategies have been systematically developed over recent decades with significant research focused on the infusion of white blood cells (the immune

system's backbone) directly into patients. The essence and most effective of such resultant protocols, calls for these white blood cells to be activated and expanded outside the body in a relentless effort to target them directly at tumor cells. This type of strategy is called adoptive immunotherapy. Research has shown that three types of white blood cells seem to be most potent at fighting tumors:

natural killer cells (NKs) natural killer T cells (NKTs) cytotoxic T lymphocytes (CTLs)

Natural killer cells are particularly worthwhile, as they maintain the body's first-line defense against cancer and viruses. They possess the uncanny ability to recognize and destroy such invading cells by attaching to them and injecting a type of cellular poison that explodes the cells. They are also adept at recognizing cancer cells that have spread (metastasized) from the primary disease site.

Envita - International Leader in Stage 4 Cancer and Advanced Leukemia Immunotherapy

A bevy of published literature has demonstrated the effects of adoptive immune therapy in cancer patients. Envita's renowned medical associates assessed the most noteworthy of these studies and focused on the strengths and weaknesses of each therein. Their vision established a protocol that incorporates only the most outstanding procedures known to expedite expansion and application of cells as a powerful immune therapy. Our protocols are based on the most current published research in the field, from our most prestigious national and global hospitals/ universities.

Leukemia Presents New but Addressable Twist to Stage 4 Cancer Immunotherapy

Because leukemia is a cancer of white blood cells, and most immunotherapy strategies try to enhance the ability of white blood cells to battle cancer, leukemia has posed unique queries to researchers in this field. Only quite recently have adoptive immunotherapy strategies become available to patients combating leukemia. The major obstacle was the power to isolate normal, non-leukemic cells that could fight against the cancerous ones.

Published research has confirmed that NKs, NKTs, and CTLs can, with certainty, be isolated, expanded and activated from the blood of leukemia patients. Although patients with acute lymphoid leukemia (ALL) or chronic lymphoid leukemia (CLL) have very few normal lymphocytes, successful expansion of NK, NKT, and CTLs was indicated.1-5 Likewise, these cells can be generated from patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), whose lymphocytes are non-cancerous but typically dysfunctional.6-11 In the majority of cases, the NKs, NKTs, and CTLs expanded from leukemia patients were able to marginalize tumor cells in laboratory tests.2-4, 6-11 There remains persuasive evidence that in acute leukemia patients who have gone into remission, the ability of their natural killer cells to eradicate cancer cells in laboratory tests is a strong indicator of continued remission.12 Those patients with higher natural killer cell activity enjoyed lengthier remission periods than those with lower NK activity.12

Immunotherapy for Leukemia and Other Stage 4 Cancers Finally Taken Seriously by Traditional Care Providers

A recent clinical trial instituted at the Mayo Clinic in Rochester, Minnesota utilized natural killer cells in patients with poor prognosis acute myeloid leukemia. Complete remissions were experienced in 5 out of 19 patients after receiving these NK cell infusions.13 Naturally, the proposed use of natural killer cell therapy in earlier stage patients is presently under consideration. In other printed scientific studies, the presence of activated NK cells and other tumor-fighting immune cells have been found to be major factors in the response of cancer patients to drugs such as thalidomide and Gleevec.14,15

Envita - World Leader in Stage 4 Leukemia and Cancer Immunotherapy

Envita Natural Medical Center currently utilizes NK, NKT, and T lymphocytes as supportive immunotherapy for cancer patients, including those with Leukemia. Envita's proprietary immune therapy vaccine is appropriately labeled AAIT (autologous adoptive immune therapy,) and there are four major cell types involved - the most prevalent being natural killer cells and T cells.

Our AAIT therapy increases a patient’s own antitumor immune cells into the billions, analyzes them for activation markers, assesses their cancer killing ability in the lab. Only at that juncture, when the serum vaccine is fully optimized, is it re-infused into the patient. The infusion of activated natural killer cells is remarkably more effective than any indirect stimulation of natural killer cell activity.

Envita AAIT - A Powerful Option to Fight Leukemia

Enhancing the immune system is a major boon to fighting cancer, but this vaccine-driven routine may be improved through subtraction. In simple terms, we can heighten results by not only bolstering critical components of the immune system, but simultaneously depleting it of negative factors that impede its functionality.

Spurred by scientific research and clinical results, AAIT offers a powerful option for cancer patients who are determined to fight cancer while keeping their immune system intact. Enhancing the immune system is a definite plus to targeting cancer, but this vaccine-driven routine may be added upon through subtraction. In lay terms, we can improve results by not only bolstering critical components of the immune system, but simultaneously depleting it of negative factors that impede its functionality.

It is universally accepted that cancer cells effect the release of T-regulatory cells, or "negative T cells." The frequency of these cells correlate directly with specific cancer stages - respective to each cancer type. The more advanced the cancer, the higher the T-regulatory cells.

Naturally, through intervention and deeming to thwart these cells, along with other key enzymes that block critical immune system, cancer cell-killing action will be expedited exponentially. Just theorize that your immune system is being targeted and is essentially to go, yet something in your body suddenly applies the brakes. This is precisely what most advanced cancer patients must tolerate in regards to high regulatory T cells. Envita's treatment protocols create a targeted vaccine by using the body's most potent cancer killers, but also depletes that portion of the immune system which inhibits the body from functioning efficiently in such regard. Pointedly, there is no treatment (conventional or alternative) that can be effective in the later stages of cancer, if these negative T-cells are not effectively regulated downward.

Unlike other immune therapies circulated in published literature, Envita’s AAIT can be used as a solitary treatment. AAIT can also be recommended in conjunction with other therapies that will act to enhance the effects of cells once they are in the patient. This is a key improvement over many of the scientific published studies. Envita’s AAIT therapy is not just bent on expanding cells in the laboratory; the ultimate goal is to also expand them and keep them activated after they are infused back into the body.

Envita Mexico - Now Administering Advanced AAIT Immunotherapy to Treat Leukemia and Stage 4 Cancer

The activated natural killer cells in Envita's AAIT are considerably more effective in the realm of tumor obliteration than other immunotherapy treatments, heretofore, proffered in Mexico or across the globe. Prompted by scientific research and clinical results, Envita's AAIT offers a persuasive option for leukemia cancer patients who are determined to battle cancer while keeping their immune system intact. If you have questions concerning Envita’s AAIT, please consult with our team of physicians as well as our patient educators. This particular therapy is offered in Envita Mexico's international cancer center.

References

1) Ritz J. Expansion of natural killer cells for use in acute lymphoid leukemia. Haematologica. 2005 Jun;90(6):723A.

2) Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foa R. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica. 2005 Jun;90(6):785-92.

3) Cardoso AA, Veiga JP, Ghia P, Afonso HM, Haining WN, Sallan SE, Nadler LM. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood. 1999 Nov 15;94(10):3531-40.

4) Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003 Oct;17(10):1973-80.

5) Lee YK, Kay NE. Reconstitution of innate immunity in B-chronic lymphocytic leukemia: time to reconsider the possibilities. Leukemia. 2003 Oct;17(10):1945-7.

6) Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002 Jan;116(1):78-86.

7) Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma. 2003 Sep;44(9):1457-62.

8) Orleans-Lindsay JK, Deru A, Craig JI, Prentice HG, Lowdell MW. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy. Clin Exp Immunol. 2003 Sep;133(3):467-75.

9) Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996 Mar 15;87(6):2476-85.

10) Verfaillie C, Miller W, Kay N, McGlave P. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood. 1989 Aug 1;74(2):793-7.

11) Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998 Nov 1;92(9):3318-27.

12) Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol. 2002 Jun;117(4):821-7.

13) Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051-7. Epub 2005 Jan 4.

14) Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan;128(2):192-203.

15) Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crepineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mecheri S, Tursz T, Zitvogel L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004 Aug;114(3):379-88.

Immunotherapy Envita is one of the leading natural medical centers in the U.S. and abroad. Envita treats a large range of conditions, and our mainly focused areas such as cancer, disease, heart disease, For more Informations Please Visit Our www.envita.com Website.

 by PROXY FILTOP